Loading...

ZURZUVAE Commercialization And OB/GYN Screening Will Unlock New Opportunities

Published
29 Mar 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$8.73
0.6% undervalued intrinsic discount
24 Jul
US$8.68
Loading
1Y
-9.6%
7D
-1.4%

Author's Valuation

US$8.730.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 1.73%

Shared on24 Apr 25
Fair value Decreased 5.40%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 17.3x to 19.1x.

Shared on09 Apr 25
Fair value Increased 0.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.11%

AnalystConsensusTarget has increased revenue growth from 58.9% to 66.1%, increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 35.9x to 17.2x and decreased shares outstanding growth rate from 0.0% to 0.0%.